Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients
10.3969/j.issn.1674-7445.2024009
- VernacularTitle:HIV阳性实体器官移植受者的免疫抑制药物管理
- Author:
Kun SHAO
1
;
Xianghui WANG
;
Peijun ZHOU
Author Information
1. 200025 上海,上海交通大学医学院附属瑞金医院泌尿科;上海交通大学医学院附属瑞金海南医院国际移植医疗康复诊疗中心
- Keywords:
Human immunodeficiency virus;
Solid organ transplantation;
Combination antiretroviral therapy;
Immune induction;
Calcineurin inhibitor;
Mammalian target of rapamycin inhibitor;
Mycophenolic acid;
Glucocorticoid
- From:
Organ Transplantation
2024;15(4):570-574
- CountryChina
- Language:Chinese
-
Abstract:
The application of combination antiretroviral therapy(cART)has significantly prolonged the life expectancy of patients infected with human immunodeficiency virus(HIV).However,viral infection and adverse reactions of cART drugs make patients more prone to organ failure.Solid organ transplantation has become a standard treatment for HIV-infected patients with end-stage organ failure.Nevertheless,among HIV-positive soild organ transplant recipients,multiple problems remain to be resolved,such as increased incidence of graft rejection,increased infection risk,drug toxicity and drug interaction between cART therapy and immunosuppressive drugs,etc.It is extremely challenging to deliver appropriate management for HIV-positive soild organ transplant recipients.Therefore,the application of immune induction therapy,calcineurin inhibitors,mammalian target of rapamycin(mTOR)inhibitors and other immunosuppressive drugs in HIV-positive soild organ transplant recipients was reviewed,aiming to provide reference for subsequent management of immunosuppression in HIV-positive soild organ transplant recipients.
